Heme Biosynthesis

Tetrapyrroles—macrocyclic compounds composed of four pyrrole-derived rings linked by methine (=CH–) or methylene (–CH₂–) bridges—have been termed the "pigments of life" (by Alan R. Battersby) because they form the prosthetic cores of the most foundational bioenergetic and catalytic systems on Earth: heme (an iron-chelated porphyrin essential for oxygen transport in hemoglobin/myoglobin, mitochondrial respiration in cytochromes, and xenobiotic metabolism in cytochrome P450 monooxygenases), chlorophylls and bacteriochlorophylls (magnesium-chelated chlorins and bacteriochlorins driving photosynthesis), cobalamin / Vitamin B₁₂ (a cobalt-chelated corrin), siroheme (iron-chelated isobacteriochlorin for sulfite and nitrite reduction), and coenzyme F₄₃₀ (a nickel-chelated hydrocorphin in methanogenic archaea).

Despite their structural diversity, all natural tetrapyrroles are synthesized from a single universal five-carbon precursor, 5-aminolevulinic acid (ALA / δ-aminolevulinic acid), which is condensed in eight conserved enzymatic steps into protoporphyrin IX and metallated into heme b (protoheme IX). Across the tree of life, two evolutionary pathways generate 5-aminolevulinic acid:

1. The Shemin (C₄) Pathway: Restricted to α-proteobacteria and non-photosynthetic eukaryotes (animals, fungi, and kinetoplastids), in which a single pyridoxal 5'-phosphate (PLP)-dependent enzyme, 5-aminolevulinate synthase (ALAS), condenses glycine and succinyl-CoA inside the mitochondrion (discovered via ¹⁵N and ¹⁴C isotopic tracing by David Shemin and David Rittenberg in 1945–1953).
2. The Beale (C₅) Pathway: Present in Archaea, most Bacteria, and the chloroplasts of plants and algae, in which intact five-carbon L-glutamate ligated to tRNA^Glu is reduced by glutamyl-tRNA reductase (HemA) to glutamate-1-semialdehyde (GSA) and transaminated by GSA-2,1-aminomutase (HemL) into ALA.

In humans, inherited or acquired partial deficiencies in any of the eight enzymes of the heme biosynthetic pathway cause the porphyrias—a group of metabolic disorders characterized by the cytotoxic accumulation of neurovisceral porphyrin precursors (ALA and porphobilinogen, causing acute neurovisceral attacks) or photoreactive porphyrinogen/porphyrin macrocycles (which generate singlet oxygen, ¹O₂, under 400–410 nm Soret-band light, causing severe cutaneous blistering and photosensitivity).

The Mitochondrial Shemin (C₄) Pathway and ALAS Catalysis

In metazoans and fungi, the first and rate-limiting step of heme biosynthesis occurs in the mitochondrial matrix, catalyzed by homodimeric 5-aminolevulinate synthase (ALAS, EC 2.3.1.37):

The reaction proceeds via a classic PLP-stabilized carbanion/quinonoid mechanism:

1. The active-site lysine (Lys313 in human erythroid ALAS2) forms an internal aldimine with the pyridoxal 5'-phosphate (PLP, Vitamin B₆) cofactor.
2. Incoming glycine displaces Lys313 via transaldimination to form an external aldimine.
3. Deprotonation of the Cα proton of glycine generates a resonance-stabilized quinonoid carbanion intermediate, which attacks the thioester carbonyl of citric acid cycle-derived succinyl-CoA to form an enzyme-bound α-amino-β-ketoadipate intermediate after CoA-SH release.
4. Decarboxylation of the glycine-derived carboxyl group releases CO₂ and yields 5-aminolevulinic acid (ALA).

Vertebrates encode two tissue-specific isozymes of ALAS with distinct transcriptional and post-transcriptional regulatory circuits:

• ALAS1 (Housekeeping / Ubiquitous Isozyme, Chromosome 3p21): Expressed in all tissues (especially the liver to supply heme for cytochrome P450 enzymes). ALAS1 is under tight negative feedback repression by free heme: high intracellular heme binds heme-regulatory motifs (HRMs, Cys–Pro dipeptide motifs) in the N-terminal mitochondrial targeting sequence of precursor ALAS1 to block mitochondrial import, destabilizes ALAS1 mRNA, and promotes Lon-protease degradation of matrix ALAS1. Conversely, barbiturates, anticonvulsants, steroid hormones, and fasting activate the nuclear receptors CAR, PXR, and PGC-1α, inducing massive hepatic ALAS1 transcription—the primary trigger of acute neurovisceral attacks in hepatic porphyrias.
• ALAS2 (Erythroid-Specific Isozyme, X Chromosome Xp11.21): Expressed exclusively in developing erythroblasts (which synthesize ~85% of total body heme for hemoglobin). Unlike ALAS1, ALAS2 is not repressed by heme; instead, the 5' untranslated region (5'-UTR) of ALAS2 mRNA contains a stem-loop Iron-Responsive Element (IRE). Under iron deficiency, apo-Iron Regulatory Proteins (IRP1/IRP2) bind the 5'-UTR IRE and block ribosomal translation of ALAS2. Only when sufficient iron enters the erythroblast to assemble [4Fe–4S] clusters on IRP1 (and degrade IRP2) is ALAS2 translated, coupling protoporphyrin IX synthesis strictly to iron availability. Loss-of-function mutations in ALAS2 cause X-linked sideroblastic anemia (XLSA) (characterized by iron-overloaded ringed sideroblasts in bone marrow that frequently respond to high-dose pyridoxine / Vitamin B₆), whereas C-terminal gain-of-function mutations cause X-linked protoporphyria (XLP).

Following ALA synthesis in the mitochondrial matrix, the pathway exports ALA to the cytosol for four steps before returning to the mitochondria for the final three oxidations and iron insertion:

1. Step 2 — ALA Dehydratase (Porphobilinogen Synthase, ALAD, Cytosol): Homo-octameric ALA dehydratase (ALAD / PBGS) catalyzes the asymmetric Knorr-type condensation of two molecules of ALA (one bound at the P-site contributing the propionyl side chain, and one bound at the A-site contributing the acetyl side chain) via two active-site lysine Schiff bases (Lys199 and Lys252) to form the monopyrrole porphobilinogen (PBG) with elimination of 2 H₂O. Mammalian ALAD requires a catalytic Zn²⁺ cofactor coordinated by a cysteine-rich cluster (Cys122, Cys124, Cys132). Lead (Pb²⁺) has picomolar affinity for this thiol cluster, displacing Zn²⁺ and potently inhibiting ALAD—resulting in elevated urinary ALA and neurotoxicity in lead poisoning (plumbism).
2. Step 3 — Hydroxymethylbilane Synthase (PBG Deaminase, HMBS, Cytosol): Hydroxymethylbilane synthase (HMBS / uroporphyrinogen I synthase) polymerizes four molecules of porphobilinogen (PBG) head-to-tail (with deamination of four NH₃ molecules) onto a unique covalently bound dipyrromethane cofactor attached to a cysteine residue, releasing the linear tetrapyrrole 1-hydroxymethylbilane (pre-uroporphyrinogen).
3. Step 4 — Uroporphyrinogen III Synthase (UROS, Cytosol): Linear hydroxymethylbilane is chemically unstable and will cyclize non-enzymatically in seconds into the symmetrical, biologically dead-end uroporphyrinogen I isomer (which cannot be converted to heme). Uroporphyrinogen III synthase (UROS) intercepts hydroxymethylbilane and catalyzes a rapid spiro-pyrrolenine rearrangement that flips Ring D by 180° before macrocycle closure, yielding the asymmetric, physiologically essential uroporphyrinogen III isomer (where the acetate and propionate side chains follow the sequence A–P, A–P, A–P, P–A around rings A, B, C, and D).
4. Step 5 — Uroporphyrinogen Decarboxylase (UROD, Cytosol): Homodimeric uroporphyrinogen decarboxylase (UROD)—one of the most proficient cofactor-independent decarboxylases known (k_cat/k_non ≈ 10¹⁷)—sequentially decarboxylates all four acetate (–CH₂COO⁻) side chains of uroporphyrinogen III (starting at ring D and proceeding clockwise to A, B, and C) into methyl (–CH₃) groups, producing coproporphyrinogen III.
5. Step 6 — Coproporphyrinogen Oxidase (CPOX, Mitochondrial Intermembrane Space): Coproporphyrinogen III is imported across the outer mitochondrial membrane into the intermembrane space, where oxygen-dependent coproporphyrinogen oxidase (CPOX) oxidatively decarboxylates the two propionate side chains on rings A and B into vinyl (–CH=CH₂) groups, yielding protoporphyrinogen IX. (Anaerobic bacteria use an unrelated radical SAM enzyme, HemN, for this step).
6. Step 7 — Protoporphyrinogen Oxidase (PPOX, Inner Mitochondrial Membrane): FAD-dependent protoporphyrinogen oxidase (PPOX) abstracts six electrons and six protons (using 3 O₂ → 3 H₂O₂) from the methylene bridges of colorless, non-planar protoporphyrinogen IX to generate the fully conjugated, planar, intensely colored 18-π-electron aromatic macrocycle protoporphyrin IX (the target of diphenylether herbicides in plant plastids).
7. Step 8 — Ferrochelatase (FECH, Mitochondrial Matrix Face of Inner Membrane): Homodimeric ferrochelatase (FECH), which contains a structural [2Fe–2S] cluster in mammals, distorts the planar tetrapyrrole ring of protoporphyrin IX by ~36° and inserts ferrous iron (Fe²⁺) (delivered via the inner-membrane iron importer mitoferrin-1, SLC25A37) with release of 2 H⁺ to form heme b (protoheme IX). Because lead (Pb²⁺) inhibits FECH as well as ALAD, lead poisoning or iron deficiency causes ferrochelatase to insert Zn²⁺ instead of Fe²⁺, leading to diagnostic accumulation of fluorescent zinc protoporphyrin (ZPP) in erythrocytes.

Why does Acute Intermittent Porphyria (AIP) cause neurovisceral attacks without cutaneous photosensitivity, whereas Porphyria Cutanea Tarda (PCT) causes skin blistering without neurovisceral attacks?

The clinical manifestations of the porphyrias map directly onto where the metabolic block occurs relative to hydroxymethylbilane synthase (HMBS, Step 3):

• In Acute Intermittent Porphyria (AIP), partial deficiency of HMBS prevents the condensation of monopyrrole porphobilinogen (PBG) into tetrapyrrole macrocycles. When hepatic ALAS1 is induced (by CYP450-inducing drugs, progesterone, alcohol, or caloric restriction), massive quantities of ALA and PBG accumulate upstream of HMBS. Because ALA is a structural analogue of the inhibitory neurotransmitter GABA and undergoes transition-metal-catalyzed autoxidation generating reactive oxygen species, it causes severe autonomic and peripheral motor neuropathy (colicky abdominal pain, tachycardia, SIADH hyponatremia, and paralysis)—but because no tetrapyrrole rings are formed, AIP never causes skin photosensitivity.
• Conversely, in Porphyria Cutanea Tarda (PCT), hepatic uroporphyrinogen decarboxylase (UROD, Step 5) is inhibited (often promoted by iron overload, hepatitis C, alcohol, or HFE hemochromatosis mutations) without triggering runaway ALAS1 induction. Consequently, uroporphyrinogens accumulate and spontaneously oxidize into conjugated uroporphyrins, which absorb 400–410 nm Soret-band light in the dermis and transfer energy to ground-state triplet oxygen (³O₂) to generate singlet oxygen (¹O₂), causing subepidermal blisters and bullae on sun-exposed skin without neurovisceral attacks.

How do intravenous hemin and the RNAi therapeutic givosiran terminate acute hepatic porphyria attacks?

Both therapies target the hepatic ALAS1 negative feedback loop:

• Intravenous Hemin (Hematin / Heme Arginate) and High-Dose Glucose replenish the regulatory free heme pool inside hepatocytes and suppress PGC-1α, rapidly repressing hepatic ALAS1 transcription and blocking mitochondrial import of precursor ALAS1.
• Givosiran (Givlaari) is an FDA-approved N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (RNA interference) targeted specifically to hepatocyte asialoglycoprotein receptors (ASGPR) that directs RISC-mediated cleavage of hepatic ALAS1 mRNA, chronically lowering urinary ALA and PBG and preventing recurrent acute neurovisceral attacks.

1. Shemin, D., & Rittenberg, D. (1946). The biological utilization of glycine for the synthesis of the protoporphyrin of hemoglobin. Journal of Biological Chemistry, 166(2), 621–625.
2. Shemin, D., & Russell, C. S. (1953). δ-Aminolevulinic acid, its role in the biosynthesis of porphyrins and purines. Journal of the American Chemical Society, 75(19), 4873–4874. doi:10.1021/ja01115a546
3. Battersby, A. R. (2000). Tetrapyrroles: The pigments of life. Natural Product Reports, 17(6), 507–526. doi:10.1039/B002635M
4. Layer, G., Reichelt, J., Jahn, D., & Heinz, D. W. (2010). Structure and function of enzymes in heme biosynthesis. Protein Science, 19(6), 1137–1161. doi:10.1002/pro.405
5. Puy, H., Gouya, L., & Deybach, J.-C. (2010). Porphyrias. The Lancet, 375(9718), 924–937. doi:10.1016/S0140-6736(09)61925-561925-5)
6. Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017). Porphyria. New England Journal of Medicine, 377(9), 862–872. doi:10.1056/NEJMra1608634
7. Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., ... & Anderson, K. E. (2020). Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. New England Journal of Medicine, 382(24), 2289–2301. doi:10.1056/NEJMoa1913147